GO:1902004 positive regulation of amyloid-beta formation: Amyloidogenic Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1902004 describes any process that activates or increases the frequency, rate or extent of amyloid-beta formation, the central event in Alzheimer's disease pathogenesis.
• Amyloid-beta is generated by sequential cleavage of amyloid precursor protein (APP) by beta-secretase (BACE1) and gamma-secretase, and this process is positively regulated by multiple cellular and environmental factors.
• Microglial and astrocytic activation, APOE and TREM2 signaling, and metabolic reprogramming are key positive regulators of amyloid-beta formation.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise dissection of genes that positively regulate amyloid-beta formation.
• Dysregulation of this process is linked to Alzheimer's disease, and therapeutic strategies targeting positive regulators are under active investigation.
• Understanding GO:1902004 provides a mechanistic framework for identifying novel drug targets and biomarkers for Alzheimer's disease.
Description
Alzheimer's disease (AD) is characterized by the accumulation of amyloid-beta (Aβ) peptides, which are produced through the proteolytic processing of amyloid precursor protein (APP). The Gene Ontology term GO:1902004, positive regulation of amyloid-beta formation, encompasses any biological process that increases the production of Aβ peptides. This term is critical for researchers studying the molecular underpinnings of AD, as it integrates diverse signaling pathways, cellular stress responses, and metabolic changes that converge on Aβ generation. Recent studies have highlighted the role of microglial metabolism, astrocytic calcium signaling, and immune receptors in modulating Aβ formation. Understanding these positive regulatory mechanisms is essential for developing therapeutic interventions that aim to reduce Aβ burden. This article provides a comprehensive overview of GO:1902004, including its definition, biological significance, key genes, and experimental approaches for studying it.
positive regulation of amyloid-beta formation At A Glance
| GO ID | GO:1902004 |
|---|---|
| GO term | positive regulation of amyloid-beta formation |
| Ontology | biological_process |
| Synonym | activation of beta-amyloid formation, positive regulation of beta-amyloid formation, up regulation of beta-amyloid formation, up-regulation of beta-amyloid formation, upregulation of beta-amyloid formation |
| Major function | Increases the production of amyloid-beta peptides, which are central to Alzheimer's disease pathology |
| Related processes | APP processing, beta-secretase activity, gamma-secretase activity, microglial activation, neuroinflammation |
| Disease relevance | Alzheimer's disease, cerebral amyloid angiopathy |
| Research methods | CRISPR knockout/knock-in, overexpression, biochemical assays, imaging, omics |
What Is GO:1902004?
GO:1902004 is defined as any process that activates or increases the frequency, rate or extent of amyloid-beta formation. In other words, it includes all molecular and cellular events that lead to enhanced production of amyloid-beta peptides from the amyloid precursor protein (APP). This term is a child of 'positive regulation of amyloid-beta formation' and is specific to the biological process ontology. It covers both direct effects on the proteolytic cleavage machinery and indirect effects through signaling pathways that upregulate APP processing.
Why Is positive regulation of amyloid-beta formation Important in Cell Biology?
GO:1902004 is important because amyloid-beta formation is a key pathogenic event in Alzheimer's disease, and understanding its positive regulation can reveal therapeutic targets. Many genetic and environmental factors that increase AD risk do so by enhancing Aβ production, making this GO term a focal point for mechanistic studies and drug discovery.
• Central to Alzheimer's disease pathogenesis: Aβ accumulation is a hallmark of AD.
• Integrates multiple signaling pathways: microglial metabolism, astrocytic calcium, and immune receptors all converge on Aβ formation.
• Provides targets for therapeutic intervention: reducing positive regulation could lower Aβ burden.
• Links to genetic risk factors: APOE and TREM2 modulate amyloid-responsive microglia and Aβ formation.
• Relevant to biomarker development: plasma phospho-tau217 reflects Aβ pathology and can aid diagnosis.
• Enables CRISPR-based functional genomics: knockout and knock-in models can identify novel regulators.
• Connects to neuroinflammation: activated microglia and astrocytes promote Aβ production.
• Implications for drug discovery: modulating positive regulators may slow disease progression.
• Facilitates cross-species translation: human neural cell culture models recapitulate Aβ pathology.
• Supports precision medicine: targeting specific regulators based on genetic background.
What Happens During positive regulation of amyloid-beta formation?
Amyloid Precursor Protein (APP) Processing
In simple terms: APP is cut by enzymes to release amyloid-beta.
Amyloid-beta formation begins with the cleavage of APP by beta-secretase (BACE1) and gamma-secretase. Positive regulation of this process can occur through increased APP expression, enhanced BACE1 activity, or altered gamma-secretase complex composition. Studies using three-dimensional human neural cell culture models have demonstrated that APP processing and Aβ production are robustly recapitulated in vitro. Additionally, microglial metabolic changes, such as histone H4 lysine 12 lactylation, can positively regulate glucose metabolism and indirectly promote Aβ formation.
Microglial Activation and Neuroinflammation
In simple terms: Immune cells in the brain become activated and release factors that increase amyloid-beta.
Microglia are key regulators of Aβ formation. APOE and TREM2 signaling in amyloid-responsive microglia can modulate Aβ production and clearance. Soluble CSF1R promotes microglial activation and amyloid clearance, but under certain conditions, microglial activation may also enhance Aβ formation through inflammatory mediators. Positive feedback loops involving microglial glucose metabolism and lactylation further amplify this process.
Astrocytic Calcium Signaling
In simple terms: Star-shaped brain cells called astrocytes can trigger calcium signals that boost amyloid-beta.
Astrocytic mGluR5-dependent calcium hyperactivity has been shown to promote amyloid-β pathology and cognitive impairment. This suggests that astrocytic signaling is a positive regulator of Aβ formation, likely through the release of factors that influence APP processing or through direct effects on neurons.
Metabolic and Epigenetic Regulation
In simple terms: Changes in cell metabolism and gene expression can increase amyloid-beta production.
Metabolic reprogramming, such as increased glycolysis and lactylation, can positively regulate Aβ formation. Histone H4 lysine 12 lactylation in microglia creates a positive feedback loop that enhances glucose metabolism and promotes Aβ production. Gut microbial-derived metabolites, such as indole-3-propionate, can improve cognitive function and may reduce Aβ formation, indicating that metabolic factors can also negatively regulate this process.
Immune Receptor Signaling
In simple terms: Receptors on immune cells can send signals that increase amyloid-beta.
TREM2 and APOE are critical immune receptors that regulate microglial responses to amyloid. Their signaling can positively regulate Aβ formation by modulating microglial phagocytosis and inflammatory cytokine release. Engineering chimeric antigen receptor (CAR) CD4 T cells targeting Aβ has emerged as a potential therapeutic strategy, highlighting the importance of immune receptor signaling in Aβ regulation.
Key Genes Involved in GO:1902004 positive regulation of amyloid-beta formation
The following genes and proteins are key players in the positive regulation of amyloid-beta formation, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| APP | Amyloid precursor protein; substrate for Aβ production | Central to Aβ formation; mutations cause familial AD |
| BACE1 | Beta-secretase; cleaves APP to generate Aβ | Rate-limiting enzyme; target for inhibitors |
| PSEN1 | Gamma-secretase subunit; cleaves APP | Mutations cause familial AD; target for modulators |
| PSEN2 | Gamma-secretase subunit; cleaves APP | Mutations cause familial AD |
| APOE | Lipid transport; modulates microglial response to amyloid | Strong genetic risk factor for AD |
| TREM2 | Immune receptor on microglia; regulates phagocytosis | Risk factor for AD; modulates Aβ formation |
| CSF1R | Microglial survival and activation | Soluble CSF1R promotes amyloid clearance |
| mGluR5 | Astrocytic calcium signaling | Promotes Aβ pathology |
| H4K12la | Histone lactylation; metabolic regulation | Positive feedback loop in microglia |
| IL-6 | Pro-inflammatory cytokine | May enhance Aβ formation |
| TNF-alpha | Pro-inflammatory cytokine | Modulates APP processing |
| CD4 | T cell receptor; CAR T cells targeting Aβ | Therapeutic potential |
| Indole-3-propionate | Gut microbial metabolite | Improves cognition; may reduce Aβ |
| p-tau217 | Biomarker of Aβ pathology | Diagnostic tool |
| BIN1 | Endocytosis and APP processing | AD risk gene |
| CLU | Chaperone; modulates Aβ aggregation | AD risk gene |
| ABCA7 | Lipid transport; microglial function | AD risk gene |
| SORL1 | APP trafficking | AD risk gene |
How Is positive regulation of amyloid-beta formation Regulated?
Positive regulation of amyloid-beta formation is controlled by multiple signaling pathways. Microglial glucose metabolism and histone lactylation create a positive feedback loop that enhances Aβ production. Astrocytic mGluR5-dependent calcium hyperactivity promotes Aβ pathology. APOE and TREM2 signaling modulate microglial responses and can increase Aβ formation. Soluble CSF1R promotes microglial activation and amyloid clearance, but dysregulation may lead to increased Aβ. Additionally, gut microbial metabolites such as indole-3-propionate can improve cognitive function and may negatively regulate Aβ formation.
positive regulation of amyloid-beta formation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| APP | Alzheimer's disease | Knock-in mice with familial AD mutations; human neural cell cultures |
| PSEN1 | Alzheimer's disease | CRISPR knock-in of PSEN1 mutations in iPSCs |
| APOE | Alzheimer's disease | APOE4 knock-in mice; microglial cultures |
| TREM2 | Alzheimer's disease | TREM2 knockout and knock-in models |
| CSF1R | Alzheimer's disease | CSF1R knockout mice; microglial activation assays |
Alzheimer's Disease
Alzheimer's disease is the most common neurodegenerative disorder and is characterized by Aβ plaques and tau tangles. Positive regulation of amyloid-beta formation is a central mechanism in AD pathogenesis. Genetic mutations in APP, PSEN1, and PSEN2 increase Aβ production and cause early-onset familial AD. Sporadic AD is influenced by risk genes such as APOE and TREM2, which modulate microglial responses and Aβ formation. Biomarkers like plasma phospho-tau217 reflect Aβ pathology and aid in diagnosis. Therapeutic strategies targeting positive regulators of Aβ formation are under investigation.
Cerebral Amyloid Angiopathy
Cerebral amyloid angiopathy (CAA) is characterized by Aβ deposition in cerebral blood vessels, leading to hemorrhages. Positive regulation of Aβ formation contributes to CAA pathogenesis. Studies using human neural cell culture models have provided insights into Aβ production and its role in CAA. Microglial activation and neuroinflammation may exacerbate vascular Aβ deposition.
Neuroinflammation
Chronic neuroinflammation is a hallmark of AD and is closely linked to positive regulation of Aβ formation. Activated microglia and astrocytes release pro-inflammatory cytokines that can enhance APP processing and Aβ production. Metabolic reprogramming in microglia, such as increased glycolysis and lactylation, further promotes Aβ formation. Targeting neuroinflammatory pathways may reduce Aβ burden and slow disease progression.
From positive regulation of amyloid-beta formation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X positively regulate Aβ formation? | CRISPR knockout of gene X in human neural cell culture or mouse models |
| Does a specific point mutation in APP increase Aβ production? | CRISPR point mutation knock-in of APP mutations in iPSCs |
| Does overexpression of gene Y enhance Aβ formation? | Lentiviral or CRISPR activation overexpression in cell lines |
| What is the role of microglial gene Z in Aβ regulation? | Conditional knockout or knock-in in microglia |
| Can CAR T cells targeting Aβ reduce plaque burden? | Adoptive transfer of engineered T cells in AD mouse models |
| Does a gut metabolite modulate Aβ formation? | Germ-free mice or metabolite supplementation |
How to Study the positive regulation of amyloid-beta formation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss-of-function effects on Aβ formation | Identify positive regulators |
| CRISPR knock-in | Effect of specific mutations on Aβ production | Model familial AD mutations |
| Overexpression | Gain-of-function effects on Aβ formation | Test candidate genes |
| ELISA | Aβ40/Aβ42 levels | Quantify Aβ production |
| Immunohistochemistry | Amyloid plaque burden | Validate in vivo models |
| RNA-seq | Transcriptomic changes | Discover pathways |
| Proteomics | Protein expression and modifications | Identify novel regulators |
| Metabolomics | Metabolic changes | Link metabolism to Aβ formation |
CRISPR-Based Functional Genomics
CRISPR knockout, knock-in, and overexpression models are powerful tools to dissect the positive regulation of Aβ formation. For example, knocking out candidate genes in human neural cell cultures can reveal their role in APP processing and Aβ production. CRISPR activation can overexpress genes to test their effect on Aβ formation. These approaches enable high-throughput screening of regulators.
Biochemical Assays for Aβ Production
Aβ levels can be measured using ELISA, Western blot, or mass spectrometry. These assays are used to quantify the effect of genetic manipulations on Aβ formation. Human neural cell culture models have been validated for Aβ production and are suitable for biochemical assays.
Imaging and Histology
Amyloid plaques can be visualized using immunohistochemistry or amyloid-binding dyes such as thioflavin S. In vivo imaging with PET tracers allows longitudinal monitoring of Aβ deposition in animal models. These methods are essential for validating the impact of positive regulators on Aβ pathology.
Omics and Bioinformatics
Transcriptomics, proteomics, and metabolomics can identify global changes in gene expression and metabolic pathways associated with Aβ formation. Bioinformatics analyses can integrate these datasets to uncover novel regulators and networks. Single-cell RNA sequencing of microglia and astrocytes has revealed cell-type-specific regulators of Aβ formation.
How CRISPR Can Be Used to Study GO:1902004 positive regulation of amyloid-beta formation
Knockout
CRISPR knockout of candidate genes in human neural cell cultures or mouse models can determine whether a gene is necessary for Aβ formation. For example, knocking out BACE1 reduces Aβ production, confirming its positive regulatory role. Knockout of microglial genes such as TREM2 can alter Aβ formation and plaque deposition.
Point Mutation
CRISPR point mutation knock-in can introduce familial AD mutations in APP or PSEN1 to model increased Aβ formation. These models are valuable for studying the mechanistic effects of specific mutations on APP processing. Point mutations in APOE (e.g., APOE4) can also be introduced to assess their impact on Aβ regulation.
Knock-in
Knock-in of reporter genes or tags (e.g., GFP, luciferase) into endogenous loci allows real-time monitoring of APP processing and Aβ formation. Tagged knock-in models can be used to track protein localization and interactions. Knock-in of human APP with disease mutations in mice recapitulates Aβ pathology.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression can increase the expression of candidate genes to test their effect on Aβ formation. Overexpression of APP or BACE1 increases Aβ production, while overexpression of negative regulators reduces it. These models are useful for gain-of-function studies.
How EDITGENE Supports positive regulation of amyloid-beta formation Research
Researchers studying positive regulation of amyloid-beta formation-related genes often need to determine whether a candidate gene is causally involved in Aβ production. This requires precise genetic manipulation and functional validation. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of amyloid-beta formation research.
Frequently Asked Questions About positive regulation of amyloid-beta formation
What is GO:1902004?
GO:1902004 is a Gene Ontology term for 'positive regulation of amyloid-beta formation', describing any process that increases the production of amyloid-beta peptides.
What genes are involved in positive regulation of amyloid-beta formation?
Key genes include APP, BACE1, PSEN1, PSEN2, APOE, TREM2, CSF1R, and mGluR5, among others.
How is amyloid-beta formed?
Amyloid-beta is formed by sequential cleavage of APP by beta-secretase (BACE1) and gamma-secretase.
What diseases are associated with positive regulation of amyloid-beta formation?
Alzheimer's disease and cerebral amyloid angiopathy are the primary diseases linked to increased Aβ formation.
How can CRISPR be used to study positive regulation of amyloid-beta formation?
CRISPR knockout, knock-in, and overexpression models can identify and validate genes that regulate Aβ production.
What are the therapeutic implications of targeting positive regulators of amyloid-beta formation?
Inhibiting positive regulators may reduce Aβ burden and slow Alzheimer's disease progression.
What is the role of microglia in amyloid-beta formation?
Microglia can positively regulate Aβ formation through inflammatory signaling and metabolic reprogramming.
How do APOE and TREM2 affect amyloid-beta formation?
APOE and TREM2 modulate microglial responses to amyloid, influencing Aβ formation and clearance.
What biomarkers reflect amyloid-beta formation?
Plasma phospho-tau217 is a biomarker that reflects Aβ pathology and can aid in diagnosis.
What research methods are used to study positive regulation of amyloid-beta formation?
Methods include CRISPR screens, biochemical assays, imaging, and omics technologies.
Conclusion
GO:1902004, positive regulation of amyloid-beta formation, is a critical biological process in Alzheimer's disease and related disorders. Understanding the genes and pathways that enhance Aβ production provides insights into disease mechanisms and potential therapeutic targets. CRISPR-based models and advanced omics approaches are indispensable for dissecting this regulation. EDITGENE offers comprehensive services to support researchers in this endeavor, from knockout and knock-in models to library screening and bioinformatics.
References
- 1. Pan RY et al.. 2022. Positive feedback regulation of microglial glucose metabolism by histone H4 lysine 12 lactylation in Alzheimer's disease.. Cell Metab 34(4):634-648.e6 PMID: 35303422
- 2. Li L et al.. 2025. Gut microbial-derived indole-3-propionate improves cognitive function in Alzheimer's disease.. Sci Adv 11(48):eadw8410 PMID: 41313780
- 3. Nguyen AT et al.. 2020. APOE and TREM2 regulate amyloid-responsive microglia in Alzheimer's disease.. Acta Neuropathol 140(4):477-493 PMID: 32840654
- 4. Choi SH et al.. 2014. A three-dimensional human neural cell culture model of Alzheimer's disease.. Nature 515(7526):274-8 PMID: 25307057
- 5. Palmqvist S et al.. 2025. Plasma phospho-tau217 for Alzheimer's disease diagnosis in primary and secondary care using a fully automated platform.. Nat Med 31(6):2036-2043 PMID: 40205199
- 6. Yang T et al.. 2026. Astrocytic mGluR5-dependent calcium hyperactivity promotes amyloid-β pathology and cognitive impairment.. Brain 149(1):134-149 PMID: 40377015
- 7. Boskovic P et al.. 2026. Engineering chimeric antigen receptor CD4 T cells for Alzheimer's disease.. Proc Natl Acad Sci U S A 123(7):e2530977123 PMID: 41662521
- 8. Zhang L et al.. 2025. Soluble CSF1R promotes microglial activation and amyloid clearance in alzheimer's disease.. J Neuroinflammation 22(1):245 PMID: 41152873
